A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

NCT05572463 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor Strategy

Conditions

Unresectable Cutaneous Melanoma
Metastatic Cutaneous Melanoma

Interventions

COMBINATION_PRODUCT: Sintilimab + IBI110

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Collaborators

[object Object]